睿知中国医院研究地图
候选清单

即将招募冠心病不分期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Micro-axial Flow Pump-Supported PCI in Complex Coronary Artery Disease With Ischemic LV Dysfunction

ClinicalTrials.gov 上登记的一项冠心病开放试验。牵头方不是本站收录的医院;本站收录的 1 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 研究中心中国医学科学院阜外心血管病医院Fuwai Hospital北京医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07678021,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 2

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(2 项)收起清单
  1. 18 岁 至 80 岁;性别:不限

    登记记录的入选字段

  2. Women who are pregnant or breastfeeding;

    排除标准第 15 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;分期或严重程度(按试验的定义);既往治疗;日常活动能力;化验:血常规、肝肾功能;影像与可测量病灶;试验排除的其他疾病。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07678021,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. The subject is aged ≥18 years;
  2. The subject has been diagnosed with chronic or acute coronary syndrome and has a left ventricular ejection fraction <35%;
  3. After comprehensive evaluation by the cardiac team, it is considered that the subject may benefit from PCI treatment;
  4. The subject has signed an informed consent form approved by the ethics committee, has good compliance after discharge, and is willing to undergo clinical follow-up.
  5. At least two vascular occlusive lesions (with the diameter of the occluded vessel >2.5mm) or unprotected left main coronary artery disease, and meeting one or more complex procedural criteria, or three-vessel disease, and meeting two or more complex procedural criteria;

排除标准:Exclusion Criteria:

  1. Received mechanical circulatory assistance devices (including IABP, ECMO, Impella, etc.) before randomization;
  2. Acute myocardial infarction within 7 days or undergoing thrombolytic therapy;
  3. Combined with aortic dissection, pulmonary embolism, or severe pulmonary hypertension;
  4. Patients with cardiogenic shock or hemodynamic instability;
  5. Cardiopulmonary resuscitation was performed before randomization;
  6. Mechanical complications (including ventricular perforation, interventricular septal perforation, mitral valve chordae rupture, etc.) confirmed before randomization and subsequent to acute myocardial infarction;
  7. The mechanical circulatory assist device cannot be implanted or there are contraindications (including but not limited to left ventricular mural thrombus, artificial aortic valve or cardiac contractile device, moderate or severe aortic stenosis, moderate or severe aortic regurgitation, presence of stents in peripheral vascular access, tortuosity, dissection, and other severe vascular lesions that hinder the implantation of the investigational device, aortic aneurysm or severe malformation abnormalities, blood cell fragility or hemolytic blood system diseases, hypertrophic or hypertrophic obstructive cardiomyopathy, etc.);
  8. Severe abnormalities in platelets, with a count below 50×10\^9/L or above 600×10\^9/L;
  9. Active visceral hemorrhage or hemorrhagic stroke occurs within 1 month;
  10. Unable to use antiplatelet or anticoagulant drugs;
  11. Has a history of drug allergy and cannot tolerate conventional cardiovascular drug therapy and intraoperative medications;
  12. Severe renal insufficiency, requiring or expected to require long-term dialysis treatment;
  13. Severe active infection, puncture site infection, sepsis, or septicemia;
  14. Life expectancy is less than or equal to 1 year;
  15. Women who are pregnant or breastfeeding;
  16. Severe right heart failure or severe tricuspid regurgitation;
  17. Participation in other clinical trials has not yet reached the primary endpoint;
  18. Other situations that are unforeseen or deemed unsuitable by the researcher's comprehensive judgment.

引自 ClinicalTrials.gov, NCT07678021, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07678021,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07678021